For its fourth fiscal quarter (ending December 31), Acadia Pharmaceuticals Inc (NASDAQ: ACAD) has reported a 207% increase in E.P.S. from $0.28 a year ago to $0.86 in the current quarter. E.P.S. were $1.37 for the latest four quarters through December 31 versus $-0.37 for the same period a year ago — a decline of -470%.
Recent Price Action
On 2/26/25, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) stock declined slightly by -0.05%, closing at $19.00. However, this decline was accompanied by exceptionally low trading volume at 46% of normal. The stock has declined -3.7% during the last week but has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Acadia Pharmaceuticals has a current Value Trend Rating of F (Lowest Rating). This rating combines inconsistent signals from two proprietary PTR measures of a stock’s attractiveness. Acadia Pharmaceuticals has a very low Appreciation Score of 11 but a neutral Power Rating of 54, resulting in the Lowest Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment